The metabolism of Dexamethasone can be decreased when combined with Doxycycline. Dexamethasone may increase the fluid retaining activities of Fluoxymesterone. The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Dexamethasone. The therapeutic efficacy of Insulin Human can be decreased when used in combination with Dexamethasone. The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Dexamethasone. The serum concentration of Dexamethasone can be decreased when it is combined with Bosentan. The serum concentration of Dexamethasone can be increased when it is combined with Mifepristone. Oleandrin may decrease the cardiotoxic activities of Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Lovastatin. The serum concentration of Dexamethasone can be decreased when it is combined with Mitotane. Dexamethasone may increase the fluid retaining activities of Testosterone Propionate. The serum concentration of Dasatinib can be decreased when it is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Indomethacin is combined with Dexamethasone. The serum concentration of Edoxaban can be increased when it is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Fleroxacin. The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Metamizole is combined with Dexamethasone. Dexamethasone may increase the hypokalemic activities of Amphotericin B. The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Benzydamine is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Etodolac is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Leflunomide. The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Adapalene is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Diflunisal is combined with Dexamethasone. The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Physostigmine. The risk or severity of adverse effects can be increased when Tenoxicam is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Floctafenine is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Suprofen is combined with Dexamethasone. Digitoxin may decrease the cardiotoxic activities of Dexamethasone. The therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Anisodamine is combined with Dexamethasone. The serum concentration of Cobicistat can be decreased when it is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Flumequine. The therapeutic efficacy of Glyburide can be decreased when used in combination with Dexamethasone. The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Dexamethasone. Dexamethasone may increase the hypokalemic activities of Metolazone. The risk or severity of adverse effects can be increased when Loxoprofen is combined with Dexamethasone. The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Dexamethasone. Trastuzumab may increase the cardiotoxic activities of Dexamethasone. The bioavailability of Dexamethasone can be decreased when combined with Aluminum hydroxide. The serum concentration of Dexamethasone can be decreased when it is combined with Rifapentine. The therapeutic efficacy of Miglitol can be decreased when used in combination with Dexamethasone. The therapeutic efficacy of Gliclazide can be decreased when used in combination with Dexamethasone. The serum concentration of Dexamethasone can be increased when it is combined with Tibolone. The therapeutic efficacy of Miglustat can be decreased when used in combination with Dexamethasone. The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Dexamethasone. The serum concentration of Triazolam can be decreased when it is combined with Dexamethasone. The serum concentration of Dexamethasone can be increased when it is combined with Estriol. The bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide. The risk or severity of adverse effects can be increased when Fenbufen is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Cinoxacin. The bioavailability of Dexamethasone can be decreased when combined with Aluminium. The serum concentration of Dexamethasone can be decreased when it is combined with Nevirapine. The serum concentration of Romidepsin can be decreased when it is combined with Dexamethasone. The therapeutic efficacy of Glimepiride can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with G17DT. Dexamethasone may increase the hypokalemic activities of Polythiazide. Indacaterol may increase the hypokalemic activities of Dexamethasone. The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Dexamethasone. The bioavailability of Dexamethasone can be decreased when combined with Bismuth Subcitrate. The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Dexamethasone. The therapeutic efficacy of Exenatide can be decreased when used in combination with Dexamethasone. The serum concentration of Dexamethasone can be decreased when it is combined with Rifampicin. The risk or severity of adverse effects can be increased when Mesalazine is combined with Dexamethasone. The serum concentration of Dexamethasone can be decreased when it is combined with Rifabutin. The risk or severity of adverse effects can be increased when Masoprocol is combined with Dexamethasone. The serum concentration of Dexamethasone can be decreased when it is combined with Fosphenytoin. The risk or severity of adverse effects can be increased when Teriflunomide is combined with Dexamethasone. The bioavailability of Dexamethasone can be decreased when combined with Almasilate. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dexamethasone. The bioavailability of Dexamethasone can be decreased when combined with Magaldrate. The risk or severity of adverse effects can be increased when Lisuride is combined with Dexamethasone. Proscillaridin may decrease the cardiotoxic activities of Dexamethasone. The serum concentration of Dexamethasone can be increased when it is combined with Ivacaftor. The serum concentration of Dexamethasone can be increased when it is combined with Diethylstilbestrol. The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Venlafaxine. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Rotavirus Vaccine. The serum concentration of Bosutinib can be increased when it is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Nalidixic Acid. The serum concentration of Dexamethasone can be increased when it is combined with Mestranol. The metabolism of Dexamethasone can be decreased when combined with Posaconazole. The risk or severity of adverse effects can be increased when Aceclofenac is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Triptolide is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Ginkgo biloba. The serum concentration of Dexamethasone can be increased when it is combined with Vemurafenib. The metabolism of Dexamethasone can be decreased when combined with Olaparib. Dexamethasone may increase the fluid retaining activities of Mesterolone. The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Dexamethasone. Dexamethasone may increase the fluid retaining activities of Testosterone. Dexamethasone may increase the hypokalemic activities of Bendroflumethiazide. The therapeutic efficacy of Phenformin can be decreased when used in combination with Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Erythromycin. The serum concentration of Dexamethasone can be increased when it is combined with Netupitant. The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Tinoridine is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Tranilast is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Natalizumab. Dexamethasone may increase the fluid retaining activities of Stanozolol. The serum concentration of Dexamethasone can be decreased when it is combined with Siltuximab. The risk or severity of adverse effects can be increased when Docetaxel is combined with Dexamethasone. The serum concentration of Pitavastatin can be increased when it is combined with Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Diltiazem. The therapeutic efficacy of Buformin can be decreased when used in combination with Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Atazanavir. The risk or severity of adverse effects can be increased when Methylergometrine is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Hepatitis B Vaccine (Recombinant). The risk or severity of adverse effects can be increased when Semapimod is combined with Dexamethasone. The serum concentration of Conivaptan can be increased when it is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Salmonella typhi ty21a live antigen. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Atorvastatin. The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Resveratrol is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Enoxacin. Mivacurium may increase the adverse neuromuscular activities of Dexamethasone. The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexamethasone. Bevacizumab may increase the cardiotoxic activities of Dexamethasone. The serum concentration of Cyclosporine can be decreased when it is combined with Dexamethasone. Rapacuronium may increase the adverse neuromuscular activities of Dexamethasone. The therapeutic efficacy of Liraglutide can be decreased when used in combination with Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Clarithromycin. The therapeutic efficacy of Nateglinide can be decreased when used in combination with Dexamethasone. The serum concentration of Fosamprenavir can be decreased when it is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Demecarium. The risk or severity of adverse effects can be increased when Salsalate is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexamethasone.